The US Food and Drug Administration granted Alere, Inc a CLIA waiver for the Alere i influenza A & B test, a molecular test that detects and differentiates influenza A and B in under 15 minutes. Unlike PCR testing, this isothermal nucleic acid amplification technology (iNAT) does not require lengthy and complex thermocycling or DNA purification and can therefore deliver PCR-caliber results more quickly, and in a broad range of health care settings, including hospitals, physician offices, and clinics. Additional tests on the Alere i platform are currently in development.